世界主要国における非小細胞肺癌（NSCLC）治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Epidemiology 9
2.3 Etiology and Pathophysiology 9
2.3.1 Adenocarcinoma 11
2.3.2 Squamous Cell Carcinoma 13
2.3.3 Large Cell Carcinoma 15
2.3.4 Immunotherapy 16
2.4 Symptoms 17
2.5 Diagnosis 17
2.6 Prognosis 19
2.7 Treatment 20
2.7.1 Treatment Algorithm 21
2.7.2 First-Line Treatment 21
2.7.3 Maintenance Therapy 23
2.7.4 Second-Line Treatment 24
2.7.5 Third-Line Therapy 25
2.7.6 Adjuvant Therapy 25
2.8 Marketed Product Heatmaps 25
3 Marketed Products 29
3.1 Overview 29
3.2 Chemotherapies 29
3.3 Alimta – Eli Lilly 29
3.4 Abraxane – Celgene Corporation 30
3.5 Tarceva – Roche 31
3.6 Iressa – AstraZeneca 32
3.7 Gilotrif – Boehringer Ingelheim 33
3.8 Xalkori – Pfizer 34
3.9 Avastin – Roche 34
3.10 Cyramza – Eli Lilly 35
3.11 Opdivo – Bristol-Myers Squibb 36
3.12 Zykadia – Novartis 37
3.13 Alectinib – Roche 38
3.14 Conclusion 39
4 NSCLC Pipeline 40
4.1 Overview 40
4.2 Mechanisms of Action and Targets in the Pipeline 43
4.3 Clinical Trials 45
4.3.1 Failure rate 45
4.3.2 Clinical Trial Duration 48
4.3.3 Clinical Trial Size 50
4.3.4 Clinical Trial Summary 55
4.4 Late-Stage Pipeline Product Profiles 56
4.4.1 Ganetespib – Synta Pharmaceuticals 56
4.4.2 Yervoy – Bristol-Myers Squibb 57
4.4.3 Custirsen – Oncogenex Pharmaceuticals 59
4.4.4 Atezolizumab – Roche 60
4.4.5 Necitumumab – Eli Lilly 62
4.4.6 Patritumab – Daiichi Sankyo 63
4.4.7 Selumetinib – AstraZeneca 64
4.4.8 Rociletinib – Clovis Oncology 65
4.4.9 AZD-9291 – AstraZeneca 67
4.4.10 Vaxira – Recombio 68
4.4.11 Keytruda – Merck 70
4.4.12 TG4010 – Transgene 71
4.4.13 Veliparib – AbbVie 72
4.4.14 Abemaciclib – Eli Lilly 73
4.4.15 Bavituximab – Peregrine Pharmaceuticals 75
4.5 Pipeline Heatmaps and Product Competitiveness 76
4.5.1 Product Competitiveness Framework 79
4.6 Pipeline Conclusion 80
5 Market Forecast 81
5.1 Geographical Markets 81
5.1.1 Global Markets 82
5.1.2 North America 83
5.1.3 Top Five EU Countries 86
5.1.4 Japan 91
5.2 Drivers and Barriers 93
5.2.1 Drivers 93
5.2.2 Barriers 93
6 Strategic Consolidations 95
6.1 Major Licensing Deals 95
6.1.1 Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 98
6.1.2 Novartis Enters into Licensing Agreement with Antisoma 98
6.1.3 Ariad Pharma Enters into a Collaboration Agreement with Merck 99
6.1.4 Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib 99
6.2 Major Co-Development Deals 99
6.2.1 Pfizer Enters into Co-Development Agreement with Merck 102
6.2.2 Merck Enters into Co-Development Agreement with Endocyte 102
6.2.3 GlobeImmune Enters into Agreement with Celgene 103
6.2.4 Amgen Enters into Co-Development Agreement with Takeda Pharmaceutical 103
7 Appendix 104
7.1 References 104
7.2 Abbreviations 108
7.3 Research Methodology 109
7.3.1 Secondary Research 110
7.3.2 Marketed Product Profiles 110
7.3.3 Late-Stage Pipeline Candidates 110
7.3.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 111
7.3.5 Product Competitiveness Framework 111
7.3.6 Pipeline Analysis 111
7.3.7 Forecasting Model 112
7.3.8 Deals Data Analysis 113
7.4 Expert Panel Validation 113
7.5 Contact Us 113
7.6 Disclaimer 113